PEPFAR Partnership for Pediatric AIDS Treatment
The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) Partnership for Pediatric AIDS Treatment was launched in 2006. This public-private partnership includes innovator and generic pharmaceutical companies and multilateral organizations such as UNAIDS, WHO and UNICEF. The initiative will identify scientific obstacles to treatment for children, take practical steps to address key barriers, share best practices and develop systems for clinical and technical support.
In addition to making medicines available at preferential prices to PEPFAR, Abbott is also working with PEPFAR to advance treatment for children with HIV in developing countries.
Bristol-Myers Squibb is an active partner in the PEPFAR Partnership for Pediatric AIDS Treatment, working to find solutions to issues concerning pediatric HIV treatment, formulations and access. In 2004, Bristol-Myers Squibb agreed to allow the FDA to make right of reference to its confidential dossiers and product registration files to facilitate approval of generic combination products under the PEPFAR program.
Gilead is an active member of the Accelerated Access Initiative and several United Nations’ agency working groups, as well as the PEPFAR Partnership for Pediatric AIDS Treatment.
GlaxoSmithKline, whose HIV/AIDS programs are now run by ViiV Healthcare, has been a major supplier of ARVs to PEPFAR at not-for-profit prices and has also participated in the State Department’s program to expand the number of pediatric formulations for HIV medicines that are appropriate for PEPFAR and other child access programs in the developing world.
Merck & Co., Inc. is an active member of the PEPFAR Partnership for Pediatric AIDS Treatment, working to identify scientific and technical solutions to improving access to antiretroviral treatment for children living with HIV/AIDS in resource-limited settings.